SEC Form 4 · accession 0001140361-26-024929

GYRE THERAPEUTICS, INC. · GYRE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Operating Officer

Period of report

Jun 9, 2026

Accepted (ET)

Jun 11, 2026 · 4:01 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001124105

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jun 9, 2026	M	14,500	$0.75	A	714,500	D
Common Stock^F1	Jun 9, 2026	S	14,500	$6.14	D	700,000	D
Common Stock	Jun 10, 2026	M	6,418	$0.75	A	706,418	D
Common Stock^F2	Jun 10, 2026	S	6,418	$6.21	D	700,000	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$0.75	Jun 9, 2026	M	14,500	D	—	Oct 31, 2030	Common Stock	14,500	847,919	D
Stock Option (Right to Buy)^F3	$0.75	Jun 10, 2026	M	6,418	D	—	Oct 31, 2030	Common Stock	6,418	841,501	D

F1The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0597 to $6.19. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.11 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3These options are vested in full.